7.14
전일 마감가:
$7.22
열려 있는:
$7.12
하루 거래량:
33,345
Relative Volume:
0.10
시가총액:
$5.93M
수익:
-
순이익/손실:
$-14.93M
주가수익비율:
-0.0268
EPS:
-266.137
순현금흐름:
$-15.87M
1주 성능:
+5.15%
1개월 성능:
-29.58%
6개월 성능:
-96.70%
1년 성능:
-99.42%
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
RNAZ을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RNAZ
Transcode Therapeutics Inc
|
7.14 | 5.75M | 0 | -14.93M | -15.87M | -266.14 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
(RNAZ) On The My Stocks Page - news.stocktradersdaily.com
Transcode Therapeutics Appoints Dr. Phillip D. Zamore To Science Advisory Board - marketscreener.com
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - citybiz
TransCode Therapeutics appoints RNA expert to advisory board - Investing.com
TransCode Therapeutics appoints RNA expert to advisory board By Investing.com - Investing.com Nigeria
Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan
TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World
Certain Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
When (RNAZ) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announcement | RNAZ Stock News - GuruFocus
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World
Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
(RNAZ) Investment Report - news.stocktradersdaily.com
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan
TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com India
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus
Offerings News Live Feed - Stock Titan
Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com
TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com
TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus
TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com
TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN
For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com
Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com
CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com
Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com
Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com
Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com
why Astera Labs Inc [ALAB] is a Good Choice for Investors After New Price Target of $111.21 - dbtnews.com
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - Yahoo Finance
TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - The Globe and Mail
TransCode Therapeutics (RNAZ) Advances Clinical Trial of TTX-MC1 - GuruFocus
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):